Change Notification UK National Blood Services  No. 11 2018

Pregnancy

These changes apply to the Bone Marrow and Peripheral Blood Stem Cell Donor Selection Guidelines

**Obligatory**

**Must not donate:**

a) If pregnant.

b) Less than one week has passed for every completed week of a recent pregnancy, **up to a maximum of 6 months**.

c) Resulted in a malignant (invasive) Hydatidiform mole.

d) Resulted in a non-malignant (non-invasive) Hydatidiform mole and treatment and follow up is ongoing.

e) It is less than 7 days from the last dose of methotrexate.

**Discretionary**

If more than 6 months post-partum, accept. Donors may need advice regarding the safety of continuing to breast feed, if relevant.

**See if Relevant**

Surgery  
Transfusion

**Additional Information**

Methotrexate is now increasingly used to medically treat ectopic pregnancy, to avoid surgery and protect the fallopian tube. A week is needed for any residual methotrexate to clear the system.

For donors donating by PBSC, it is recommended that mothers who wish to continue breast-feeding after donation should not feed their infant (but may express and discard milk) from the point of first G-CSF administration to one week following the last dose of G-CSF.

For donors donating by BM, it is recommended that mothers who wish to continue breast-feeding after donation should not feed their infant (but may express and discard milk) from the point of administration of any sedating agent to 24 hours following the last dose of sedating anaesthetic or opiate analgesia.

\Continued
**Reason for Change**

The deferral period for pregnancies lasting six months or more has been reduced as iron stores are known to recover 6 months post delivery. Registries should give donors advice about breast-feeding such as that given by the WMDA.


---

**Dr Sheila MacLennan**  
**Professional Director - Joint UKBTS Professional Advisory Committee**

📞 Direct Dial: (0113) 820 8638  
📧 sheila.maclennan@nhsbt.nhs.uk